KDIGO has updated its Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD), originally published in 2012. A draft of the KDIGO 2025 Anemia in CKD Guideline is now available for public review. We invite you to review this update and share your comments and suggestions. KDIGO will prepare a final version for publication based on feedback received during the public review period. Please submit your feedback no later than Friday, November 22.
Download the Anemia in CKD Guideline Public Review Draft and corresponding Data Supplement from the guideline suite (right). You can submit feedback via the survey link below. Only completed surveys will be considered. Please also note that by agreeing to provide feedback on a KDIGO draft guideline document, you permit KDIGO to acknowledge your participation as a reviewer in the final publication.
The KDIGO Anemia in CKD Guideline provides comprehensive guidance on diagnosing, evaluating, and treating anemia in adults and children with CKD, both those receiving and not receiving dialysis (hemodialysis and peritoneal dialysis). It covers the use of iron, erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs), and red blood cell (RBC) transfusions.
The development of the guideline followed an explicit process of evidence review and appraisal, with recommendations based on a rigorous analysis of data from randomized controlled trials published through April 2023. The guideline uses the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach to evaluate the certainty of evidence and strength of recommendations. It includes practice points, visual aids, and highlights policy implications, limitations of current evidence, and areas for future research. The target audience includes healthcare providers involved in the care of people with anemia and CKD, as well as people living with anemia and CKD themselves.
The Anemia in CKD Guideline is co-chaired by Dr. Jodie Babitt (United States) and Dr. Marcello Tonelli (Canada).
Click below to submit feedback via the survey. Please note that only completed surveys will be completed.
2012 ANEMIA IN CKD GUIDELINE & RESOURCES
KDIGO 2012 ANEMIA IN CKD GUIDELINE AND SUPPLEMENTARY MATERIALS
KDIGO 2012 Anemia in CKD Guideline
KDIGO 2012 Anemia in CKD Guideline Appendices
KDIGO 2012 Anemia in CKD Guideline Supplementary Tables
2012 VISUAL GUIDELINE
KDIGO 2012 Anemia Guideline At-A-Glance
Complete visual guideline recommendations to assist decision-making
2012 COMMENTARIES
Canadian Society of Nephrology
Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
KDOQI
US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
KHA-CARI
International treatment guidelines for anaemia in chronic kidney disease — what has changed? (2012)
2012 TRANSLATIONS
Chinese (Mandarin)
Japanese
Russian (Full Text)
Клинические практические рекомендации KDIGO по анемии при хронической болезни почек 2012
DISCLAIMER: USE OF THE CLINICAL PRACTICE GUIDELINES
This Clinical Practice Guideline is based upon the best information available at the time of publication. The recommendations are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health care professional making use of this Guideline is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.
